Doxorubicin and 5-fluorouracil induced accumulation and transcriptional activity of p53 are independent of the phosphorylation at serine 15 in MCF-7 breast cancer cells.

Abstract:

:The chemotherapeutic agents doxorubicin (dox) or 5-fluorouracil (5FU) are used to treat cancer cells as they cause irreparable DNA damage, inducing these aberrant cells to undergo cell death. The mediator of this process is presumed to be in part the tumor suppressor p53 which regulates genes involved in DNA repair and cell death. When MCF-7 breast cancer cells are treated with these drugs, we observed that the level of p53 and the p53 negative regulator, Mdm2, increased, as seen by others. But contrary to some reports, we observed minimal phosphorylation of p53 at serine 15 in MCF-7 cells after drug treatment. Interestingly, we determined that there was differential regulation of the kinases ATM and Chk2 with the drug treatments, likely the cause for the lack of phosphorylation of p53. We found a dramatic drop in p53 DNA binding affinity for p21 and other gene response elements (RE) after drug treatment. To determine if the p53 that accumulated in the drug treated cells was functionally active, we monitored changes in the protein products of two p53-regulated genes following drug treatment with and without the addition of a p53-specific siRNA. In response to 5FU, both p21 and Mdm2 proteins increased and that increase was alleviated if a p53-specific siRNA was added. This effect was not seen with the addition of dox. Thus, the phosphorylation at serine 15 is not necessary for the functional activation of this transcription factor. We propose a new model for the regulation of p53, Mdm2, and MdmX after drug treatment.

journal_name

Cancer Biol Ther

journal_title

Cancer biology & therapy

authors

Balmer MT,Katz RD,Liao S,Goodwine JS,Gal S

doi

10.4161/cbt.29112

subject

Has Abstract

pub_date

2014-08-01 00:00:00

pages

1000-12

issue

8

eissn

1538-4047

issn

1555-8576

pii

29112

journal_volume

15

pub_type

杂志文章
  • Mutant TNFalpha negatively regulates human breast cancer stem cells from MCF7 in vitro.

    abstract::Understanding the biology of breast cancer stem cells and trying new ways to obliterate these cells would be a key step in developing cures for breast cancer. The objective of this study was to investigate the effect of mutant TNFalpha on human breast cancer stem cells derived from MCF7 cell line under the characteriz...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.9.4885

    authors: Li Y,Kong L,Yang Y,Li K

    更新日期:2007-09-01 00:00:00

  • Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450.

    abstract:PURPOSE:The sensitivity of lung cancer to gefitinib has been found to be associated with mutations at the tyrosine kinase domain of epidermal growth factor receptor (EGFR), yet similar observations are not available in other solid tumors. We recently identified mutations in the EGFR kinase domain in primary esophageal ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.2.2318

    authors: Guo M,Liu S,Herman JG,Zhuang H,Lu F

    更新日期:2006-02-01 00:00:00

  • Small molecule inhibitors of IRES-mediated translation.

    abstract::Many genes controlling cell proliferation and survival (those most important to cancer biology) are now known to be regulated specifically at the translational (RNA to protein) level. The internal ribosome entry site (IRES) provides a mechanism by which the translational efficiency of an individual or group of mRNAs c...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1071729

    authors: Vaklavas C,Meng Z,Choi H,Grizzle WE,Zinn KR,Blume SW

    更新日期:2015-01-01 00:00:00

  • BRCA1 phosphorylation: biological consequences.

    abstract::More than a decade has passed since BRCA1, breast cancer tumor suppressor 1, was isolated by reverse genetics in 1994. Its molecular structure and potential function have been extensively studied; both mouse genetics and a cell culture system revealed that BRCA1 is a 220,240 kD nuclear phosphoprotein, it regulates tra...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.5.5.2845

    authors: Ouchi T

    更新日期:2006-05-01 00:00:00

  • All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched.

    abstract::Male germ cell tumors (GCTs) are a model for a curable solid tumor. GCTs can differentiate into mature teratomas. Embryonal carcinomas (ECs) represent the stem cell compartment of GCTs and are the malignant counterpart to embryonic stem (ES) cells. GCTs and EC cells are useful to investigate differentiation therapy an...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.27821

    authors: Busch AM,Galimberti F,Nehls KE,Roengvoraphoj M,Sekula D,Li B,Guo Y,Direnzo J,Fiering SN,Spinella MJ,Robbins DJ,Memoli VA,Freemantle SJ,Dmitrovsky E

    更新日期:2014-04-01 00:00:00

  • Effect of DNAzymes targeting Akt1 on cell proliferation and apoptosis in nasopharyngeal carcinoma.

    abstract::The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is important in nasopharyngeal carcinoma (NPC) pathogenesis. Activated PI3K and its downstream target Akt are concernful signaling molecules and key survival factors involved in the control of cell proliferation, apoptosis and oncogenesis. The protein kinase A...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.4.7433

    authors: Yang L,Xiao L,Ma X,Tang M,Weng X,Chen X,Sun L,Cao Y

    更新日期:2009-02-01 00:00:00

  • The VEGFR-2 protein and the VEGFR-2 rs1870377 A>T genetic polymorphism are prognostic factors for gastric cancer.

    abstract:OBJECTIVE:Angiogenesis is one of the key processes in the development of malignant tumors. The vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2) signaling pathway regulates branching angiogenesis in cancer. In this study, we analyzed the associations of VEGF/VEGFR-2 proteins and VEGFR-2 genetic va...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1537575

    authors: Zhu X,Wang Y,Xue W,Wang R,Wang L,Zhu ML,Zheng L

    更新日期:2019-01-01 00:00:00

  • Endometrial cancer with congenital uterine anomalies: 3 case reports and a literature review.

    abstract:BACKGROUND:Uterine malformation is a rare deformity in woman, and only a few cases concerning endometrial cancer arising in patients with congenital uterine anomalies have been reported. Herein, we present 3 cases of endometrial cancer with different congenital uterine anomalies, and review studies involving congenital...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.1080/15384047.2017.1281495

    authors: Gao J,Zhang J,Tian W,Teng F,Zhang H,Zhang X,Wang Y,Xue F

    更新日期:2017-03-04 00:00:00

  • Survival of high grade glioma patients depends on their age at diagnosis.

    abstract:BACKGROUND:Although the prognosis for malignant gliomas is normally dismal, it's not infrequent in neurooncologist's experience to find cases with unusually prolonged survival. In order to understand what factors influence survival of high grade glioma patients, a cohort of 196 high (III-IV) grade glioma patients was i...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,多中心研究

    doi:10.4161/cbt.8.18.9209

    authors: Casartelli G,Dorcaratto A,Ravetti JL,Sola S,Vitali A,Merlo DF,Frosina G

    更新日期:2009-09-01 00:00:00

  • The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.

    abstract::The irreversible ERBB1/2/4 inhibitor neratinib has been shown to rapidly down-regulate the expression of ERBB1/2/4 as well as the levels of c-MET, PDGFRα and mutant RAS proteins via autophagic degradation. Neratinib interacted in an additive to synergistic fashion with the approved PARP1 inhibitor niraparib to kill ov...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1436024

    authors: Booth L,Roberts JL,Samuel P,Avogadri-Connors F,Cutler RE,Lalani AS,Poklepovic A,Dent P

    更新日期:2018-06-03 00:00:00

  • Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression.

    abstract::Prostate cancer is the second leading cause of cancer-related deaths in men. Fatty acid synthase (FASN) is normally upregulated during human prostate cancer onset and metastatic progression and its expression positively correlates with the development of advanced metastatic disease. However, it remains unknown what mo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.8.4447

    authors: Di Vizio D,Sotgia F,Williams TM,Hassan GS,Capozza F,Frank PG,Pestell RG,Loda M,Freeman MR,Lisanti MP

    更新日期:2007-08-01 00:00:00

  • Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab.

    abstract::The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for use in oncology. Despite clinical success the majority of patients do not respond to cetuximab and those who initially respond frequently ac...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.24342

    authors: Iida M,Brand TM,Campbell DA,Starr MM,Luthar N,Traynor AM,Wheeler DL

    更新日期:2013-06-01 00:00:00

  • Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

    abstract::Imatinib, an ABL tyrosine kinase inhibitor (TKI), has shown clinical efficacy against chronic myeloid leukemia (CML). However, a substantial number of patients develop resistance to imatinib treatment due to the emergence of clones carrying mutations in the protein BCR-ABL. The phosphoinositide 3 kinase (PI3K)/Akt/mam...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.26725

    authors: Okabe S,Tauchi T,Tanaka Y,Kitahara T,Kimura S,Maekawa T,Ohyashiki K

    更新日期:2014-02-01 00:00:00

  • Human prostate cancer ZIP1/zinc/citrate genetic/metabolic relationship in the TRAMP prostate cancer animal model.

    abstract::Prostate cancer is the second leading cause of cancer deaths among men. The availability of animal models that represent the events and factors that exist in the natural history and biology of human prostate cancer is essential in dealing with prostate cancer. In recent decades and presently, emphasis has been directe...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.12.18367

    authors: Costello LC,Franklin RB,Zou J,Feng P,Bok R,Swanson MG,Kurhanewicz J

    更新日期:2011-12-15 00:00:00

  • IDO inhibits T-cell function through suppressing Vav1 expression and activation.

    abstract:PURPOSE:Indoleamine 2,3-dioxygenase (IDO), a tryptophan catabolic enzyme, plays an important role in immune escape through suppressing T-cell function. Since Vav1 signaling pathway regulates T cell homeostasis, this study was designed to test the hypothesis that IDO induces T-cell immunosuppression through inhibiting V...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.14.8882

    authors: Li R,Wei F,Yu J,Li H,Ren X,Hao X

    更新日期:2009-07-01 00:00:00

  • SUMO in cancer--wrestlers wanted.

    abstract::SUMO (small ubiquitin-related modifier) represents a class of ubiquitin-like proteins that is conjugated, like ubiquitin, by a set of enzymes to cellular regulatory proteins, including oncogenes and tumor suppressor genes, that play key roles in the control of cell growth, differentiation and apoptosis. SUMO conjugati...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.74

    authors: Alarcon-Vargas D,Ronai Z

    更新日期:2002-05-01 00:00:00

  • Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.

    abstract::KRAS mutational status has been shown to be a predictive biomarker of resistance to anti-EGFR monoclonal antibody (mAb) therapy in patients with metastatic colorectal cancer. We report the spectrum of KRAS mutation in 1506 patients with colorectal cancer and the identification and characterization of rare insertion mu...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.28550

    authors: Tong JH,Lung RW,Sin FM,Law PP,Kang W,Chan AW,Ma BB,Mak TW,Ng SS,To KF

    更新日期:2014-06-01 00:00:00

  • Inhibiting gastric cancer-associated angiogenesis by CIAPIN1 siRNA.

    abstract::Angiogenesis plays an essential role in tumor growth and metastasis and is a promising target for cancer therapy. We characterized the effects of selective CIAPIN1 inhibition on the angiogenesis gastric cancer cell line SGC7901 by stable transfection of CIAPIN1 siRNA. Our study has been shown that CIAPIN1 play the det...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.11.8795

    authors: Yan K,He LJ,Cheng W,Ji ZZ,Zhao BX,Hui XL,Cao SS,Chen B,He L,Liang SH,Miao Y

    更新日期:2009-06-01 00:00:00

  • Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer.

    abstract::The hypoxia-inducible factor 1alpha (HIF-1alpha) plays a major role in cancer progression. The role of this transcription factor in prostate cancer development and its transition to a metastatic and androgen refractory state remains to be elucidated. Previous reports have identified the existence of single nucleotide ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.11.2091

    authors: Chau CH,Permenter MG,Steinberg SM,Retter AS,Dahut WL,Price DK,Figg WD

    更新日期:2005-11-01 00:00:00

  • Increased gene copy number of the transcription factor E2F1 in malignant melanoma.

    abstract::Translocations and unique chromosome break points in melanoma will aid in the identification of the genes that are important in the neoplastic process. We have previously shown a unique translocation in malignant melanoma cells der(12)t(12;20). The transcription factor E2F1 maps to 20q11. Increased expression of E2F h...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.4.2512

    authors: Nelson MA,Reynolds SH,Rao UN,Goulet AC,Feng Y,Beas A,Honchak B,Averill J,Lowry DT,Senft JR,Jefferson AM,Johnson RC,Sargent LM

    更新日期:2006-04-01 00:00:00

  • Serial endoscopy in azoxymethane treated mice using ultra-high resolution optical coherence tomography.

    abstract:PURPOSE:Optical coherence tomography (OCT) is a minimally invasive, depth-resolved imaging tool that can be implemented in a small diameter endoscope for imaging mouse models of colorectal cancer (CRC). In this study, we utilized ultrahigh resolution (UHR) OCT to serially image the lower colon of azoxymethane (AOM) tre...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.11.4852

    authors: Hariri LP,Qiu Z,Tumlinson AR,Besselsen DG,Gerner EW,Ignatenko NA,Povazay B,Hermann B,Sattmann H,McNally J,Unterhuber A,Drexler W,Barton JK

    更新日期:2007-11-01 00:00:00

  • Type B lactic acidosis, an uncommon paraneoplastic syndrome.

    abstract::A 67-year-old male presented with anasarca and persistent non-pruritic rash of lower extremities. Physical examination was positive for subcutaneous edema with a non-blanching rash of abdomen and lower extremities. Labs showed leukocytosis, lymphocytosis, anemia and thrombocytopenia. He also had acute kidney injury an...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2017.1394550

    authors: Wahab A,Kesari K,J Smith S,Liu Y,Barta SK

    更新日期:2018-02-01 00:00:00

  • A DNA repeat, NBL2, is hypermethylated in some cancers but hypomethylated in others.

    abstract::Hypermethylation at certain CpG-rich promoters and hypomethylation at repeated DNA sequences are very frequently found in cancers. We provide the first report that a DNA sequence (NBL2) can be either extensively hypermethylated or hypomethylated in cancer. Previously, it was shown that NBL2, a complex tandem DNA repea...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.4.1622

    authors: Nishiyama R,Qi L,Tsumagari K,Weissbecker K,Dubeau L,Champagne M,Sikka S,Nagai H,Ehrlich M

    更新日期:2005-04-01 00:00:00

  • Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription.

    abstract::Our previous studies have demonstrated that atorvastatin induces autophagy in the androgen receptor negative prostate cancer PC3 cells through inhibition of geranylgeranyl biosynthesis [Parikh et al., Prostate. 70(9): 971-981 (2010)]. This study attempts to elucidate the molecular mechanism underlying atorvastatin-ind...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.8.15978

    authors: Toepfer N,Childress C,Parikh A,Rukstalis D,Yang W

    更新日期:2011-10-15 00:00:00

  • KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression.

    abstract::Krüppel-Like Factor 4 (KLF4) functions as a tumor suppressor in some cancers, but its molecular mechanism is not clear. Our recent study also showed that the expression of KLF4 is dramatically reduced in primary lung cancer tissues. To investigate the possible role of KLF4 in lung cancer, we stably transfected KLF4 in...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.9.7.11106

    authors: Zhou Y,Hofstetter WL,He Y,Hu W,Pataer A,Wang L,Wang J,Zhou Y,Yu L,Fang B,Swisher SG

    更新日期:2010-04-01 00:00:00

  • Ras family signaling: therapeutic targeting.

    abstract::Mutationally activated and oncogenic versions of the ras genes were first identified in human tumors in 1982. This discovery prompted great interest in the development of anti-Ras strategies as novel, target-based approaches for cancer treatment. The three human ras genes represent the most frequently mutated oncogene...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.306

    authors: Cox AD,Der CJ

    更新日期:2002-11-01 00:00:00

  • Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL).

    abstract::Sirtuins (SIRT) are nicotinamide adenine dinucleotide (NAD+) dependent deacetylases or ADP- ribosyl transferases (ARTs) that deacetylate lysine residues on various proteins regulating a variety of cellular and metabolic processes. These enzymes regulate metabolism, cell survival, differentiation and DNA repair. SIRT p...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2016.1139246

    authors: Bhalla S,Gordon LI

    更新日期:2016-01-01 00:00:00

  • Molecular functions of BRCA1 in the DNA damage response.

    abstract::Ten years ago, a concerted effort from several labs resulted in the cloning of BRCA1, the first of two major hereditary breast/ovarian cancer predisposition genes. Since that time, BRCA1 has been linked to several key nuclear functions connected with the prevention of genomic instability. In particular, BRCA1 function...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.3.6.842

    authors: Scully R,Xie A,Nagaraju G

    更新日期:2004-06-01 00:00:00

  • Microarray data simulator for improved selection of differentially expressed genes.

    abstract::The development of microarray technology has allowed researchers to measure expression levels of thousands of genes simultaneously. Analysis of these data requires the best normalization and statistical approaches to account for the biological and technical variability inherent in the technique. To approach this probl...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.2.4.431

    authors: Singhal S,Kyvernitis CG,Johnson SW,Kaiser LR,Liebman MN,Albelda SM

    更新日期:2003-07-01 00:00:00

  • Early growth response 1 (EGR1): a gene with as many names as biological functions.

    abstract::Although most researchers in biology tend to focus on very specific issues and questions about their preferred gene or pathway, sometimes we face situations in which nature presents us with a remarkable example of a gene with multiple functions. Since the discovery of the early growth response 1 (EGR1) gene in the mid...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.20.9804

    authors: DeLigio JT,Zorio DA

    更新日期:2009-10-01 00:00:00